methyl N-[(1R)-2-[(2S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate | 1255936-26-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(1R)-2-[(2S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
• CAS: 1255936-26-5
• 化学式: C₂₃H₂₃BrN₄O₃
• 分子量: 483.365
• InChiKey: KHHWATWEQQAKDU-VQTJNVASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  87.3
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  左旋苯甘氨酸 在 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 sodium hydroxide 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.33h， 生成 methyl N-[(1R)-2-[(2S)-2-[5-(4-bromophenyl)-1H-imidazol-2-yl]pyrrolidin-1-yl]-2-oxo-1-phenylethyl]carbamate
  参考文献：
  名称：

  FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

  摘要：

  公开号：

  EP2545060B1

文献信息

• [EN] FUSED TRICYCLIC ARYL COMPOUNDS USEFUL FOR THE TREATMENT OF VIRAL DISEASES<br/>[FR] COMPOSÉS ARYLES TRICYCLIQUES CONDENSÉS UTILES POUR LE TRAITEMENT DE MALADIES VIRALES
  申请人：SCHERING CORP

  公开号：WO2010132538A1

  公开（公告）日：2010-11-18

  The present invention relates to novel Fused Tricyclic Aryl Compounds, compositions comprising at least one Fused Tricyclic Aryl Compound, and methods of using the Fused Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient.

  本发明涉及新型融合三环芳基化合物、包含至少一种融合三环芳基化合物的组合物，以及使用这些融合三环芳基化合物治疗或预防患者中HCV感染的方法。
• [EN] ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C<br/>[FR] COMPOSÉS ANTIVIRAUX DE TROIS FRACTIONS D'ARYLE LIÉES POUR TRAITER DES MALADIES TELLES QUE L'HÉPATITE C
  申请人：SCHERING CORP

  公开号：WO2010138791A1

  公开（公告）日：2010-12-02

  The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56

  本发明涉及新型联苯并三环化合物，包含至少一种联苯并三环化合物的组合物，以及利用联苯并三环化合物治疗或预防患者HCV感染的方法。在一个方面，本发明提供了式（I）的化合物及其药用盐，其中：式（II）的化合物的非限制性示例包括化合物56。
• ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR
  申请人：ZHAN Zheng-Yun James

  公开号：US20140364429A1

  公开（公告）日：2014-12-11

  Provided are compounds antiviral compounds represented by formula Ia and Ib: that are highly potent as HCV NS5A inhibitors, where the structural variables are as defined herein. These compounds are useful in, for example, inhibiting Hepatitis C virus and treating Hepatitis C virus infections.

  提供的化合物是由公式Ia和Ib表示的抗病毒化合物：它们作为HCV NS5A抑制剂非常有效，其中结构变量如此定义。这些化合物在抑制丙型肝炎病毒和治疗丙型肝炎病毒感染等方面非常有用。
• COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
  申请人：AB Pharma Ltd

  公开号：EP3153515A1

  公开（公告）日：2017-04-12

  This patent discloses a group of HCV inhibiting chemical compounds, their stereoisomers, tautomers, isotope isomers, hydrates, esterified or amidated prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions and applications thereof, and the application of the mixture of one or more of these compositions in the preparation of HCV inhibitory drugs. The described compounds can effectively inhibit HCV NS5A, and can be used for preparing medicines for the prevention and treatment of HCV-NS5A infection.

  本专利公开了一组抑制HCV的化合物、它们的立体异构体、同分异构体、同位素异构体、水合物、酯化或酰胺化原药、药学上可接受的盐、药物组合物及其应用，以及其中一种或多种组合物的混合物在制备HCV抑制药物中的应用。所述化合物能有效抑制 HCV NS5A，可用于制备预防和治疗 HCV-NS5A 感染的药物。
• ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C
  申请人：Zeng Qingbei

  公开号：US20120258078A1

  公开（公告）日：2012-10-11

  The present invention relates to novel Linked Tricyclic Aryl Compounds, compositions comprising at least one Linked Tricyclic Compound, and methods of using Linked Tricyclic Aryl Compounds for treating or preventing HCV infection in a patient. in one aspect, the present invention provides Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein: Non-limiting examples of the Compounds of Formula (II) include compound 56